Rank 95 • MedTech & Devices
Senseonics
Develops Eversense, a long-term, fully implantable continuous glucose monitoring system.
Visit website- Signal Score
- 79.6
- Total raised
- $250M
- Stage
- Public
- Founded
- 1996
- Headquarters
- Germantown, USA
- Region
- North America
Their signal
Stands out with the world's only long-lasting implantable CGM sensor, offering continuous glucose tracking for up to 365 days from a single insertion.
Signal Score 79.6editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in MedTech & Devices
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.